Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 19

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 19
---
 to expend significant financial resources in our employee recruitment and retention efforts. Many
of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different
risk profiles, and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for
career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience
constraints that will harm our ability to implement our business strategy and achieve our business objectives.

In
addition, we have scientific and clinical advisors who assist us in formulating our development and clinical strategies. These advisors
are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability
to us. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies
that may compete with those of the Company.

We
currently have limited marketing capabilities and no sales organization. If we do not establish sales and marketing capabilities on our
own or through third parties, we will be limited in our commercialization to license deals with third parties following successful Phase
II trials.

We
currently have limited marketing capabilities and no sales organization. If we do not establish sales and marketing capabilities on our
own or through third parties, we will be limited in our commercialization to license deals with third parties following successful Phase
II trials. To commercialize our clinical assets, if approved, in the U.S., Canada, the European Union, and other jurisdictions that we
seek to enter, we must build our marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements
with third parties to perform these services, and we may not be successful in doing so. Although our management team has experience in
the marketing, sale, and distribution of pharmaceutical products from prior employment at other companies, we as a company have no prior
experience in the marketing, sale, and distribution of pharmaceutical products and there are significant risks involved in building and
managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales
leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing
team. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities would adversely impact
the commercialization of these products. We may choose to collaborate with additional third parties that have direct sales forces and
established distribution systems,